Australian software automates data mining of CR dose

Sep 8, 2009
2009 09 04 13 32 21 103 Snapshot 700
2009 09 04 13 32 21 103 Snapshot 700
The dose data-mining software analyzes CR exposure indices, highlighting underexposed studies in blue and overexposed exams in red. Image courtesy of Curtise Ng, Ph.D.

close

Latest in Clinical News
Moscone Center Astro
ASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progression
September 29, 2025
Digital Innovations Shaping the Future of Radiology
Sponsored
Digital Innovations Shaping the Future of Radiology
September 24, 2025
Survey Form 400
NAPT survey results show promise for proton therapy
September 29, 2025
Moscone Center Astro
ASTRO: Low-dose RT effective for treating knee osteoarthritis
September 29, 2025
Related Stories
2009 09 04 13 36 21 888 Snapshot 250
PACS/VNA
Australian software automates data mining of CR dose
2009 09 03 11 44 43 712 Reilly Kevin 150
Nuclear Medicine
How to maintain a successful PET/CT program
2009 08 31 09 03 29 44 Chang thumb 09 09
Advanced Visualization
Fuzzy 3D ultrasound CAD sharpens breast cancer sensitivity
Digital Innovations Shaping the Future of Radiology
Sponsor Content
Digital Innovations Shaping the Future of Radiology
More in Clinical News
ASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progression
By Will Morton
Two cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.
September 29, 2025
Moscone Center Astro
ASTRO: Contemporary IMRT comparable to proton therapy for throat cancer
By Liz Carey
Phase III U.K. TORPEdO trial investigated proton beam therapy for reducing long-term treatment-related toxicities.
September 29, 2025
Moscone Center Astro
NAPT survey results show promise for proton therapy
By Amerigo Allegretto
Proton therapy continues to experience increased clinical use, but barriers to care continue to limit its potential.
September 29, 2025
Survey Form 400
ASTRO: Low-dose RT effective for treating knee osteoarthritis
By Amerigo Allegretto
Research presented at ASTRO 2025 showed the effectiveness of low-dose radiation therapy for treating knee osteoarthritis.
September 29, 2025
Moscone Center Astro
ASTRO: Genomic test predicts benefit of hormone therapy in prostate cancer
By Will Morton
Patients with a prostate tumor subtype known as luminal B had meaningful benefits from the addition of apalutamide to secondary radiotherapy.
September 29, 2025
Moscone Center Astro
CPDC launches Cadena Research for radiopharmaceutical development
By AuntMinnie.com staff writers
The CPDC has launched Cadena Research, a new preclinical CRO offering support for early-stage radiopharmaceuticals.
September 29, 2025
Radiotherapy2 400
Polarean enters xenon MRI supply agreement with UVA Health
By AuntMinnie.com staff writers
Polarean Imaging has entered into a new supply agreement with UVA Health to support the clinical use of Xenon MRI.
September 29, 2025
Lungs 3 D Research 400
Minicarm.com named exclusive distributor for Hologic's Fluoroscan
By AuntMinnie.com staff writers
Minicarm.com is offering sales support and training for the remaining inventory of Hologic's Fluoroscan Insight FD Mini C-Arm.
September 29, 2025
Business Deal Corporate 400
ASTRO: Patient navigation key to mitigating RT treatment disparities
By Kate Madden Yee
"Patients are lost and need to be navigated," said presenter Christina Chapman, MD, of Baylor College of Medicine in Houston.
September 29, 2025
Moscone Center Astro
ASTRO: Radiotherapy offers opportunities beyond cancer treatment
By Kate Madden Yee
Radiotherapy isn't just for cancer treatment, according to talks at ASTRO 2025 in San Francisco.
September 28, 2025
Moscone Center Astro
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Accuray introduces Stellar adaptive radiotherapy system
By AuntMinnie.com staff writers
Stellar expands the range of available radiation delivery options offered by Accuray.
September 26, 2025
Accuray Astro 2019 Social
Page 1 of 3687
Next Page